Asklepios BioPharmaceutical

The Asklepios BioPharmaceutical company also known as AskBio, was founded in 2001 for development of gene therapy. AskBio created the platform of gene therapy on the basis of an adenoassotsiirovanny virus (AAV) and the related line of highly productive cages and also cooperated with Columbus Venture Partners over creation of the production site for gene therapy against still incurable diseases. This platform is under authority of the Viralgen company created by AskBio together with Columbus.

History

2020: Bayer purchased Asklepios BioPharmaceutical for $2 billion

At the end of October, 2020 Bayer concluded the bargain on acquisition of Asklepios BioPharmaceutical for $2 billion. The transaction provides additional payments in the amount of $2 billion more at achievement of the predeterminated performance parameters. As a result of purchase of Bayer will receive control over the platform of gene therapy which is used for search of drugs against Parkinson's disease, a disease to the Pump and heart failure.

It is known that the AskBio company developed technology of self-complementary DNA which was applied during creation of gene therapy to treatment of muscular dystrophy of Zolgensma and also used the opportunities for development of gene therapy of neuromuscular, cardiovascular and metabolic violations.

Bayer purchased the biotechnical-company for $2 billion

The German company Bayer estimated company assets at $4 billion taking into account achievement of certain endpoints. Under the agreement the most part from them (75%) should be reached within the next five years. Bayer intends to use the AskBio platform for the solution of rather large polygenetic problems. Besides, the company considers the possibilities of use of business of Viralgen as a basis for development of gene therapy on the basis of AAV. After closing of the transaction of Bayer will allow AskBio to work independently within new division of cellular and gene therapy.^[1]

Notes